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In 1980, we reported that patients with aortic stenosis (AS)
who had a low mean gradient (30 mm Hg) and low
ejection fraction (0.30) fared poorly following aortic valve
replacement (AVR) (1). We also demonstrated that while
ejection fraction may be reduced in AS either because of
afterload mismatch or contractile dysfunction, in patients
with low transvalvular gradient, afterload mismatch is rarely
the explanation for reduced ejection performance. Rather
these patients suffer from severe muscle dysfunction in turn
explaining their poor outcome. In our small sample, all
patients with a low gradient did poorly but only four such
patients were included. Subsequent reports confirm a worse
prognosis for such patients (2–4), but these larger series
have universally demonstrated that some patients with low
gradient/low ejection fraction gain substantial benefit by
improvement in symptoms following AVR. Benefit occurs
despite only a modest improvement in the ejection perfor-
mance (4). The failure of ejection performance to improve
very much is consistent with contractile dysfunction rather
than afterload mismatch as the major cause of reduced
preoperative performance. Indeed when afterload mismatch
is the major culprit, ejection performance improves dramat-
ically. Persistent left ventricular dysfunction in turn no
doubt explains why both early and midterm postoperative
mortality is substantially greater than is seen in patients with
aortic stenosis with preserved ventricular function.
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While previous reports demonstrated that patients with
low gradient/low ejection fraction aortic stenosis could be
operated on successfully, it remained unclear whether they
did better and lived longer with surgery than with medical
therapy until now. The authors of the article published in
this month’s Journal (5), in my view, conclusively demon-
strate that there is not only symptomatic benefit but also a
mortality benefit to AVR in this group of patients. While
theirs was not a randomized controlled trial (and none is
likely to be performed in this group of patients), an excellent
attempt was made to compare apples with apples between
the patients who did and did not receive an aortic valve
replacement. While no doubt some biases still exist, the
preoperative data in the two groups suggest that the groups
were comparable and while some differences were probably
present but not accounted for, it is highly unlikely that any
explanation other than the success of AVR would explain
the obvious benefit to those patients who received a valve.
While clearly it is ill-advised for patients to get to this
far-advanced stage in their disease (and surely no physician
would allow it to occur on purpose), these data are persua-
sive that we should recommend AVR for most patients in
this category.
While the study by Pereira et al. (5) is a clear advance, in
my view, at least one major question remains unresolved and
awaits further study. This question is whether patients with
low gradient/low ejection fraction with what I have referred
to as aortic pseudostenosis would fare as well as patients
with true AS following AVR (6). Aortic pseudostenosis is a
condition in which the valve area in the low gradient/low
output state is calculated to be small but when increased
flow is introduced into the valve, there is only a small or
even no increase in gradient resulting in a large increase
(0.3 cm2) in valve area when area is recalculated using the
new higher flow data (7–9). It seems logical that in such
cases where it is not true AS but rather a weakened ventricle
incapable of opening an only mildly diseased valve, that
AVR would not benefit such patients. This should differ
from the situation in which increased flow causes a large
increase in gradient with little change in valve area, a
condition in which presumed truly severe AS has led to
ventricular dysfunction and, therefore, AVR might be
expected to improve the condition. In the current study, it is
not clear how often these techniques were used preopera-
tively to separate patients although in some cases they were.
However the question remains: Were there patients in the
pseudostenosis category who benefited from AVR or is the
practice of using increased flow to ferret out this situation
still justified? Previous studies suggest that patients with
pseudostenosis do not benefit, but the number of patients
was small (7,8).
Huge strides have been made in the preoperative assess-
ment of the patient with AS in the last decade. Otto et al.
(10) have demonstrated that patients with a transaortic jet
velocity of 4 m/s are likely to become symptomatic and,
thus, need an AVR within a few years. This knowledge
helps focus on a high risk group in whom early intervention
should help to prevent the small but definite risk of sudden
death that exists in asymptomatic patients. Das et al. (11)
have helped to further stratify this group by finding that
exercise testing reveals patients who denied symptoms or
have treadmill-induced symptoms which in my view should
be an indication for surgery. We have known for some time
that patients with congestive heart failure and reduced
ejection performance fare quite well at surgery provided they
have a high transvalvular gradient. Now for the first time we
have evidence that patients with reduced ejection perfor-
mance and low gradient fare better following surgery than
similar unoperated-on patients.
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Putting these data together, it seems prudent for the
asymptomatic patient with severe AS and aortic flow veloc-
ity of 4 m/s to undergo frequent close questioning
regarding symptomatic status and that almost all such
patients should also undergo exercise testing which I believe
(but cannot prove) would reduce the risk of sudden death
from 2% to a much lower figure. At the other end of the
spectrum, until data are developed to the contrary, I believe
that the patient with low gradient/low ejection fraction
should undergo preoperative hemodynamic manipulation to
increase cardiac output. Those with truly severe AS who
have increased gradient as output increases should undergo
AVR.
For now, I believe that patients with aortic pseudosteno-
sis should be treated medically unless and until new data
demonstrate that they also benefit from AVR.
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